Cell therapy specialist and Bayer (BAYN: DE) subsidiary BlueRock Therapeutics is to work together with fellow USA-based company Senti Biosciences (Senti Bio).
The deal will see Senti Bio’s gene circuit technology being applied to the development of BlueRock’s next-generation engineered cell therapies.
Senti Bio is working on engineering gene circuits to reprogram cells so that they are able to sense inputs and interact with their cellular environments in a different way.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze